Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery

Main Inclusion Criteria: * Planned elective and subacute procedures with a polytetrafluoroethylene (PTFE) graft including at least one expected end-to-side anastomosis of a PTFE graft to the femoral artery (e.g. femoral-femoral cross-over, aorto-(bi)femoral, axillo-(bi)femoral, femoro-popliteal, femoro-crural bypass grafting), a PTFE patch angioplasty of the femoral artery, or an end-to-side anastomosis of a PTFE graft to an upper extremity artery in connection with arteriovenous bypass grafting for dialysis access. * The evaluation site for the planned femoral anastomosis must be a de novo site. * The participant must be heparinized during surgery. Intra-operatively (before randomization) * The participant has a need for secondary hemostatic treatment * Verification of the evaluation site being a de novo site * Verification of the surgical procedure performed as being either an end-to-side or PTFE patch angioplasty. Main Exclusion Criteria: * Thrombolytic therapy administered within 12 hours before surgery (e.g. the recombinant tissue plasminogen activator (rt-PA) Alteplase). * Liver cirrhosis. Intra-operatively (before randomization) * Severe bleeding at the anastomosis of the arterial bypass using PTFE graft prosthesis or the PTFE patch angioplasty * No bleeding (dry surgical field) at the targeted application area * Disseminated intravascular coagulopathy (DIC) * Application of topical hemostatic material including fibrin sealant/glue on the evaluation site.